Search

Nan Li,1,* Yi-Zhuo Wang,1,* Dong-Sheng Huang,1 Yi Zhang,1 Wei-Ling Zhang,1 Jian-Min Ma,2 Yan Zhou,1 Ting-Ting Liu1 1Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing, 100176, People’s Republic of China; 2Department of Ophthalmic Oncology, Beijing Tongren Hospital, Capital Medical University, Beijing, People’s Republic of China*These authors contributed equally to this workCorrespondence: Dong-Sheng HuangDepartment of Pediatrics, Beijing Tongren Hospital, Capital Medical University, No. 2, Xihuan South Road, Yizhuang Economic and Technological Development Zone, Beijing, 100176, People’s Republic of China, Email Hds5180@sina.comAim: This study aimed to summarize the clinical characteristics, treatment, and outcomes of distant metastatic retinoblastoma with event-free survival.Design: Retrospective interventional case series.Methods: We screened patients with retinoblastoma who survived without events after the comprehensive treatment of distant metastases from June 2015 to February 2021 and collected information regarding their basic characteristics, diagnosis, and treatment. All patients received systemic intravenous chemotherapy. Other treatments included surgical treatment, radiotherapy, intrathecal chemotherapy, and autologous stem cell transplantation.Results: Among 780 hospitalized patients with retinoblastoma in the pediatric ward, a total of 94 patients with retinoblastoma were diagnosed with distant metastases, and 16 patients with distant metastatic retinoblastoma who survived more than 6 months without events were screened, including eight male and eight female patients. The median age of onset was 29 (range, 11– 120) months. Among the 16 patients, central nervous system metastasis (8/16), bone metastasis (8/16), bone marrow infiltration (4/16), lymph node metastasis (4/16), and parotid gland metastasis (3/16) were presented. All patients received treatment for more than 6 months, completed their regimen by February 2021, and survived without events. The median survival time after the onset of retinoblastoma was 50.5 (range, 23– 102) months, the median survival time after metastasis was 43.5 (range, 16– 71) months, and the median event-free survival was 29.0 (range, 6– 59) months.Conclusion: Metastatic retinoblastoma may benefit from comprehensive treatments including systemic intravenous chemotherapy and hematopoietic stem cell transplantation. However, recurrence after treatment still needs attention, and patients in complete remission still need long-term follow-up.Keywords: retinoblastoma, distant metastasis, comprehensive treatment

Background & aimsThe long-term prognosis of patients with metabolic syndrome (MS) and hepatitis B virus-related hepatocellular carcinoma (HBV-HCC) after radical hepatectomy remains unclear. The purpose of this study was to elucidate the effect of MS on long-term survival for patients with HBV-related HCC after hepatectomy.MethodsPatients with HBV-HCC after hepatectomy were included. Patients were stratified into MS-HBV-HCC and HBV-HCC groups. Clinical features and surgical outcomes were compared between the two groups, and COX regression analysis was used to determine independent risk factors associated with overall survival (OS) and recurrence-free survival (RFS).Result389 patients (MS-HBV-HCC group: n=50, HBV-HCC group: n=339) were enrolled for further analysis. Baseline characteristics showed that patients with MS-HBV-HCC were associated with a high rate of elderly patients, ASA score, and co-morbid illness, but a lower rate of anatomy hepatectomy. There were no significant differences in perioperative complications. After excluding patients who relapsed or died within 90 days after surgery, multivariate Cox regression analysis showed MS was an independent risk factor of OS (HR 1.68, 95% CI 1.05-2.70, P = 0.032) and RFS (HR 1.78, 95% CI 1.24-2.57, P = 0.002).ConclusionMS is an independent risk factor for poor OS and RFS in HBV-infected HCC patients after radical hepatectomy. This suggests that we need to strengthen postoperative follow-up of the relevant population and encourage patients to develop a healthy lifestyle.

Additional file 3: Table S1. Univariable and multivariable Cox-regression analyses of predicting overall survival for patients with resected hepatocellular carcinoma who underwent adjuvant TACE in the developing cohort.

Additional file 2: Table S2. Univariable and multivariable Cox-regression analyses of predicting overall survival for patients with resected hepatocellular carcinoma who did not undergo adjuvant TACE in the developing cohort.

Supplemental material, sj-pdf-1-cmg-10.1177_2631774521993065 for Prognostic factors of resectable perihilar cholangiocarcinoma: a systematic review and meta-analysis of high-quality studies by Lei Liang, Chao Li, Hang-Dong Jia, Yong-Kang Diao, Hao Xing, Timothy M. Pawlik, Wan Yee Lau, Feng Shen, Dong-Sheng Huang, Cheng-Wu Zhang and Tian Yang in Therapeutic Advances in Gastrointestinal Endoscopy

Additional file 1. Patients and methods.

Additional file 2: Table S3. The corresponding score and the formula of our nomogram models.

Additional file 2: Figure S2. (A) Kaplan-Meier curves of overall survival between patients in the development and validation cohorts (log-rank test, P = 0.594); (B) Kaplan-Meier curves of overall survival between patients with and without adjuvant TACE in the developing cohort (log-rank test, P < 0.001); and (C) Kaplan-Meier curves of overall survival between patients with and without adjuvant TACE in the validation cohort (log-rank test, P < 0.001). Number of patients at risk and censoring were list in the box at the bottom of each plot.

Additional file 1.

Additional file 2: Figure S1. Flow chart of patient inclusion.

Supplemental material, sj-pdf-1-tag-10.1177_1756284820977693 for Survival benefits from adjuvant transcatheter arterial chemoembolization in patients undergoing liver resection for hepatocellular carcinoma: a systematic review and meta-analysis by Lei Liang, Chao Li, Yong-Kang Diao, Hang-Dong Jia, Hao Xing, Timothy M. Pawlik, Wan Yee Lau, Feng Shen, Dong-Sheng Huang, Cheng-Wu Zhang and Tian Yang in Therapeutic Advances in Gastroenterology

The primary objective of this study was to investigate the role of miR-200a in cell proliferation and epithelial-mesenchymal transition (EMT) through regulating targeting aspartate-β-hydroxylase (ASPH), which may further affect the activation of ERK/PI3K/Akt pathway. Liver cancer and adjacent tissues were collected from 72 cases of liver cancer patients with surgery in our hospital. In this study, the mRNA expression level of miR-200a was significantly decreased by real-time PCR (RT-PCR) detection. ASPH expressions, however, had an opposite tendency compared to that of miR-200a. We found a significantly negative correlation between miR-200a expressions and ASPH expressions. The survival rate of liver cancer patients with the low expressed ASPH was significantly higher than those with the high expressed ASPH. RT-PCR and Western blot results showed that low expressed miR-200a and highexpressed ASPH were found in liver cancer cell lines. Further research discovered that miR-200a transfection could significantly decrease the relative luciferase activity when it was integrated with ASPH 3'-untranslated region (3'-UTR) in HepG2 cells. Cell Counting Kit (CCK-8) detection showed that treatment with miR-200a mimics reduced cell viability, while the over-expressed ASPH increased cell viability by regulating the c-mycmrna (c-Myc) and Cyclin-D1 expressions. The EMT-related genes including E-Cadherin, N-Cadherin and Vimentin expressions were significantly increased, whereas the over-expressed ASPH exerted the opposite effects. In addition, extracellular signal regulated kinase (ERK), phosphoinositide-3-kinase (PI3K) and serine threonine kinase (AKT) were suppressed by miR-200a mimics. In conclusion, miR-200a inhibits cell proliferation and EMT in human hepatoma cells by targeting ASPH and affecting ERK and PI3K/Akt signaling pathways.

Although advancements in medical technology supporting cancer diagnosis and treatment have improved survival, these technologies still have limitations. Recently, the application of noninvasive imaging for cancer diagnosis and therapy has become an indispensable component in clinical practice. However, current imaging contrasts and tracers, which are in widespread clinical use, have their intrinsic limitations and disadvantages. Nanotechnologies, which have improved in vivo detection and enhanced targeting efficiency for cancer, may overcome some of the limitations of cancer diagnosis and therapy. Theranostic nanoparticles have great potential as a therapeutic model, which possesses the ability of their nanoplatforms to load targeted molecule for both imaging and therapeutic functions. The resulting nanosystem will likely be critical with the growth of personalized medicine because of their diagnostic potential, effectiveness as a drug delivery vehicle, and ability to oversee patient response to therapy. In this review, we discuss the achievements of modern nanoparticles with the goal of accurate tumor imaging and effective treatment and discuss the future prospects.

The excluded articles and the reasons for exclusion of the articles. (DOC 46 kb)

The pinholes on the surface of alignment layer was studied, which formed during the TFT-LCD manufacturing process and caused defects of the products. Herein, a vitally typical defect, black spot, was analyzed via FIB, SEM and OMS. The analysis results of statistical software BO (Business Objects) show that the pinhole is the main cause of the blackspot. Based on theoretical analysis and further experimental results, it is found that the hydrodynamic in stability of the solution may lead to the pinholes on the alignment layer surface, and the precure time of the alignment film solution is significantly responsible for hydrodynamic instability. It is noteworthy that the instability needs times to grow full enoughand then to influence the film structure. Therefore, the pinholes on the alignment layer surface will be reduced or eliminated if the precure time is less than or equal to that time.